- Operating Income: 50.66 billion yen, up 11% year-over-year, missing the estimate of 54.22 billion yen.
- Net Income: 37.60 billion yen, up 14% year-over-year, vastly exceeding the estimate of 15.97 billion yen.
- Net Sales: 473.12 billion yen, up 26% year-over-year, beating the estimate of 409.76 billion yen.
- Betanis/Myrabetriq/Betmiga Sales: 46.1 billion yen, down 6.3% year-over-year, but surpassing the estimate of 34.79 billion yen.
- Prograf Sales: 53.9 billion yen, up 9.8% year-over-year, exceeding the estimate of 42.64 billion yen.
- Xtandi Sales: 224.2 billion yen, up 29% year-over-year, outperforming the estimate of 199.47 billion yen.
- Research & Development (R&D) Expenses: 86.8 billion yen, up 34% year-over-year, exceeding the estimate of 74.46 billion yen.
- 2025 Year Forecast:
- Betanis/Myrabetriq/Betmiga Sales: Forecasted at 118.0 billion yen, lower than the estimate of 126.29 billion yen.
- Prograf Sales: Forecasted at 191.8 billion yen, exceeding the estimate of 184.37 billion yen.
- Xtandi Sales: Forecasted at 757.0 billion yen, slightly below the estimate of 770.64 billion yen.
- Operating Income: Forecasted at 48 billion yen.
- Net Income: Forecasted at 30 billion yen, significantly below the estimate of 46.64 billion yen.
- Net Sales: Forecasted at 1.65 trillion yen, slightly below the estimate of 1.7 trillion yen.
- Dividends: Forecasted at 74 yen, slightly below the estimate of 74.79 yen.
- FX Assumptions: 145 yen/USD, 155 yen/EUR.
- Comments:
- Sales increased for prostate cancer treatment Xtandi, urothelial cancer treatment Padcev, and acute myeloid leukemia treatment Xospata.
- Recent launches of treatments VEOZAH and IZERVAY also contributed to the increase in sales.
- R&D expenses increased due to exchange rates and investment in Primary Focus areas and strengthening of R&D functions.
- Analyst Ratings: 8 buy ratings, 8 hold ratings, 1 sell rating.
Astellas Pharma on Smartkarma
On Smartkarma, investment analyst Tina Banerjee recently published a research report on Astellas Pharma (4503 JP) titled “Astellas Pharma (4503 JP): Fx Drives FY24 Revenue; Impairment Loss Dents Profits; Pain to Continue.” In her bearish analysis, she highlighted that for FY25, Astellas Pharma is forecasting only 3% revenue growth. Furthermore, the company expects a 10% decline in core operating profit and a significant 17% decrease in net profit. Despite a ¥85B increase in revenue from FY23 to FY24, the operating and net profits suffered a significant decline of over 80% due to amortization and impairment losses on intangible assets. Astellas Pharma plans to adjust its accounting policy to stabilize core operating and net profits in FY25.
A look at Astellas Pharma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Astellas Pharma‘s long-term outlook appears promising. The company excels in dividend payouts, receiving a score of 5, which indicates a strong commitment to rewarding its investors. Additionally, Astellas Pharma demonstrates a solid momentum with a score of 4, suggesting positive growth potential in the future. While the company scores lower in terms of growth and resilience, with scores of 2 for both factors, its value proposition remains steady at a score of 3.
Astellas Pharma Inc. is a leading pharmaceutical company known for its focus on therapeutic areas such as Urology, Immunology, Oncology, and Neuroscience. With a workforce of over 17,000 employees worldwide, the company conducts research, development, manufacturing, and marketing of prescription drugs across various regions, including the US, Europe, and Asia. Astellas aims to address critical medical needs through its innovative treatments in fields like transplantation, infectious diseases, and metabolic disorders.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
